Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 332 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allergy Drug Clear all
Completed Phase 3 Interventional Results available

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04991935
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538
Drug
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 15, 2026, 5:45 PM EDT
Not yet recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

NCT07783425
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tilrekimig, Dupilumab, Placebo for Tilrekimig, Placebo for Dupilumab
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 15, 2026, 5:45 PM EDT
Not yet recruiting Phase 4 Interventional

Opzelura Experience Study

NCT07661979
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ruxolitinib, ruxolitinib and an Eczema Action Plan
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma

NCT02517047
View directory record Official record
Conditions
Asthma
Interventions
CareTRx
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Sep 15, 2026, 5:45 PM EDT
Recruiting Phase 3 Interventional

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804
View directory record Official record
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions
Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

NCT00927758
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Not applicable Interventional

Incentives for Adherence in Adolescent Asthma

NCT03515499
View directory record Official record
Conditions
Asthma, Asthma in Children
Interventions
Incentives, Medication device monitoring and reminders
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 17 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 15, 2026, 5:45 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Vaccination Responses in Young and Older Adults

NCT02654704
View directory record Official record
Conditions
Individuality, Healthy, Asthma, Immune System and Related Disorders
Interventions
Pneumococcal Vaccination
Biological
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 15, 2026, 5:45 PM EDT
Not listed No phase listed Observational

Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00897039
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
flow cytometry, immunohistochemistry staining method
Other
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 15, 2026, 5:45 PM EDT
Recruiting Phase 3 Interventional

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 15, 2026, 5:45 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application

NCT02758990
View directory record Official record
Conditions
Obesity, Rhinitis, Rhinitis, Allergic, Respiratory Sounds, Dyspnea, Headache, Migraine Disorders, Arthritis, Arthralgia, Anxiety, Sleep Initiation and Maintenance Disorders, Sleep Deprivation
Interventions
Vitamin A, Vitamin B6, Vitamin C, Nicotinamide, Vitamin D3, Vitamin E, Broccoli, Spinach, Caffeine, Coffee, Axon Eyewear, Chocolate
Dietary Supplement · Other · Device
Lead sponsor
Verifomics LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids

NCT00048009
View directory record Official record
Conditions
Asthma
Interventions
Dual Integrin Antagonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
68
States / cities
Scottsdale, Arizona • Huntington Beach, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma

NCT00048022
View directory record Official record
Conditions
Asthma
Interventions
Dual Integrin Antagonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
59
States / cities
Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Sep 15, 2026, 5:45 PM EDT
Completed No phase listed Observational

A Comparison of Two Tests for Anti-HIV Drug Resistance

NCT00006490
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2008 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Skin Testing Reagents for Penicillin Allergy

NCT01818336
View directory record Official record
Conditions
History of IgE Dependent Reaction to a Penicillin Product
Interventions
Penicillin skin test kit
Drug
Lead sponsor
AllerQuest LLC
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
13
States / cities
Homewood, Alabama • Tucson, Arizona • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 15, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional Results available

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

NCT05288062
View directory record Official record
Conditions
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions
Bone Marrow Biopsy, Dexamethasone, Lenalidomide, Pomalidomide
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 15, 2026, 5:45 PM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 15, 2026, 5:45 PM EDT
Enrolling by invitation Not applicable Interventional

Harnessing Digital Medicine to Improve Allergic Rhinitis Management in Primary Care (DMAR)

NCT06603935
View directory record Official record
Conditions
Allergic Rhinitis, Sinusitis
Interventions
QHSLab Digital Tools (AME and ARIS)
Other
Lead sponsor
QHSLab, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

NATIENS: Optimal Management and Mechanisms of SJS/TEN

NCT02987257
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions
Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 15, 2026, 5:45 PM EDT
Completed No phase listed Observational Results available

Preoperative Survey to Evaluate Patient Allergy

NCT05670756
View directory record Official record
Conditions
Allergy Drug, Allergic Reaction, Pediatric, Surgery
Interventions
Survey
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Not applicable Interventional

Electronic Monitoring of Medication Adherence in Moderate to Severe Asthma Patients

NCT02913092
View directory record Official record
Conditions
Asthma
Interventions
Electronic sensor and OW education
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
5 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma

NCT00294398
View directory record Official record
Conditions
Asthma
Interventions
ICS Prescription + Standard Asthma ED Discharge Therapy, Standard Asthma ED Discharge Therapy
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 18 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 15, 2026, 5:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety Study of a Sensitive Sensual Touch and Personal Lubricant

NCT01271036
View directory record Official record
Conditions
Inadequate Lubrication
Interventions
Formula PD-F-7716
Device
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 15, 2026, 5:45 PM EDT